New insights into the pathogenesis of membranous glomerulonephritis.
Membranous nephropathy is one of the most common glomerulopathies. Current treatments are entirely empirical, and concept-driven therapies are dramatically lacking. This review focuses on new pathophysiologic aspects of the disease, with special emphasis on the antigenic targets of pathogenic antibodies. Neutral endopeptidase - a podocyte antigen that can digest biologically active peptides - was recently identified as the target antigen of antibodies deposited in the subepithelial space of glomeruli in a subset of patients with antenatal membranous nephropathy. The mothers became immunized because they are deficient in neutral endopeptidase due to truncating mutations in the gene. Membranous nephropathy could be transferred to the rabbit by injection of mothers' immunoglobulin. Development of the renal disease was associated with anti-neutral endopeptidase IgG1. Membranous nephropathy most likely is a heterogeneous disease, although a common denominator may be that podocytes provide antigenic targets for in-situ formation of glomerular immune deposits. Identification of neutral endopeptidase and additional (podocyte) antigens and characterization of their epitopes should make it possible to design more effective and better tolerated therapies. Fetomaternal alloimmunization is a novel mechanism of renal disease that may apply to other organs as well.